Lupin Ltd

Lupin Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Lupin Ltd

₹ 2,245 -0.47%
12 May - close price
lupin.com BSE: 500257 NSE: LUPIN
About

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Key Points

Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]

Website BSE NSE
  • Market Cap ₹ 1,03,132 Cr.
  • Current Price ₹ 2,245
  • High / Low ₹ 2,494 / 1,837
  • Stock P/E 17.1
  • Book Value ₹ 659
  • Dividend Yield 0.53 %
  • ROCE 26.6 %
  • ROE 22.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 37.7% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 100 BSE 200 BSE Dollex 200

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
2,836 3,496 3,659 4,116 3,396 4,168 4,106 4,208 4,486 5,709 4,068 4,501 5,235
2,574 2,791 2,824 2,898 2,696 2,968 2,991 2,797 2,740 2,979 2,893 2,885 2,953
Operating Profit 262 705 835 1,217 700 1,200 1,115 1,411 1,746 2,730 1,176 1,617 2,282
OPM % 9% 20% 23% 30% 21% 29% 27% 34% 39% 48% 29% 36% 44%
55 28 26 23 31 38 33 -22 49 54 663 -534 537
Interest 29 16 15 11 13 14 18 20 34 19 28 36 39
Depreciation 146 140 149 145 290 141 146 153 208 177 175 179 177
Profit before tax 142 577 696 1,084 428 1,083 984 1,217 1,553 2,588 1,636 868 2,602
Tax % 16% 17% 21% 15% 10% 18% 18% 19% 17% 18% 17% 17% 17%
119 477 549 916 384 889 808 985 1,291 2,128 1,357 717 2,164
EPS in Rs 2.62 10.48 12.05 20.13 8.43 19.50 17.71 21.58 28.28 46.60 29.72 15.71 47.33
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9,752 11,344 12,626 10,081 11,356 11,026 11,056 11,772 11,259 14,666 16,968 19,513
6,375 7,357 8,134 7,992 8,504 9,116 9,012 11,560 10,295 11,216 11,574 11,709
Operating Profit 3,377 3,987 4,492 2,089 2,853 1,909 2,044 211 964 3,451 5,394 7,804
OPM % 35% 35% 36% 21% 25% 17% 18% 2% 9% 24% 32% 40%
177 187 82 128 -49 -286 129 215 210 115 176 719
Interest 5 24 29 33 35 53 41 73 98 56 84 121
Depreciation 337 306 366 390 426 519 503 514 548 725 648 707
Profit before tax 3,212 3,844 4,179 1,794 2,342 1,052 1,630 -162 527 2,785 4,837 7,694
Tax % 25% 26% 25% 25% 34% 31% 23% 17% 19% 16% 18% 17%
2,397 2,831 3,141 1,345 1,539 728 1,259 -189 425 2,326 3,973 6,367
EPS in Rs 53.34 62.83 69.56 29.74 34.01 16.06 27.74 -4.15 9.35 51.05 87.02 139.26
Dividend Payout % 14% 12% 11% 17% 15% 37% 23% -96% 43% 16% 14% 13%
Compounded Sales Growth
10 Years: 6%
5 Years: 12%
3 Years: 20%
TTM: 15%
Compounded Profit Growth
10 Years: 8%
5 Years: 38%
3 Years: 145%
TTM: 51%
Stock Price CAGR
10 Years: 4%
5 Years: 13%
3 Years: 43%
1 Year: 10%
Return on Equity
10 Years: 11%
5 Years: 12%
3 Years: 18%
Last Year: 22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 90 90 90 90 90 91 91 91 91 91 91 91
Reserves 8,938 11,823 14,690 15,695 17,027 17,383 18,475 18,059 18,321 20,512 24,187 30,042
45 392 593 17 6 6 485 951 749 105 250 1,115
1,935 1,931 2,475 2,879 2,567 3,201 2,808 3,212 3,523 4,215 3,904 4,854
Total Liabilities 11,008 14,236 17,848 18,681 19,690 20,680 21,859 22,313 22,684 24,923 28,432 36,103
2,036 2,345 3,013 3,341 3,373 3,514 3,639 3,690 4,022 4,113 4,946 4,966
CWIP 490 624 481 1,171 1,199 822 951 947 927 446 278 429
Investments 3,444 3,741 6,914 5,363 7,388 7,456 9,563 9,511 9,974 11,581 11,955 15,625
5,038 7,526 7,441 8,806 7,730 8,888 7,706 8,165 7,761 8,783 11,253 15,082
Total Assets 11,008 14,236 17,848 18,681 19,690 20,680 21,859 22,313 22,684 24,923 28,432 36,103

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,852 917 4,352 209 3,111 2,219 1,570 151 1,794 2,504 2,445 5,540
-1,178 -2,629 -1,941 725 -2,865 -740 -2,508 -372 -1,269 -1,599 -1,766 -5,649
-221 17 -160 -987 -295 -368 -53 102 -498 -867 -460 -121
Net Cash Flow 1,452 -1,696 2,252 -52 -50 1,112 -991 -118 27 38 218 -230
Free Cash Flow 2,347 195 3,411 -700 2,170 1,703 1,052 -442 1,233 1,815 1,160 5,083
CFO/OP 108% 48% 119% 34% 137% 136% 98% 1% 199% 77% 60% 86%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 94 146 113 179 120 120 105 84 87 96 122 129
Inventory Days 211 214 232 229 216 216 236 260 230 216 239 251
Days Payable 126 126 161 150 118 136 104 110 119 148 146 189
Cash Conversion Cycle 179 234 184 258 218 199 237 234 197 163 215 191
Working Capital Days 115 169 127 219 171 154 146 124 110 116 153 199
ROCE % 40% 36% 30% 11% 16% 10% 9% -1% 3% 14% 22% 27%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend as % of Sales
%

Log in to view insights

Please log in to see hidden values.

Login
ANDA Approvals (Cumulative)
Number
ANDA Filings (Cumulative)
Number
Number of Manufacturing Sites
Number
US FDA ANDA Filings (Annual)
Number
Total Workforce
Number
India Medical Representatives (Sales Force)
Number
US DMF Filings (Cumulative)
Number
US GxF TRx Volume Share
%
India Market Share - Anti-TB
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
47.07% 47.06% 47.04% 47.01% 46.99% 46.96% 46.94% 46.91% 46.90% 46.89% 46.89% 46.85%
13.93% 14.99% 16.11% 18.29% 19.32% 21.50% 22.04% 21.46% 21.25% 20.50% 21.50% 21.70%
29.08% 29.14% 29.72% 27.76% 26.77% 25.10% 24.73% 25.41% 25.55% 26.56% 25.58% 25.32%
0.28% 0.28% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
9.62% 8.52% 7.10% 6.93% 6.92% 6.44% 6.27% 6.21% 6.28% 6.06% 6.04% 6.13%
No. of Shareholders 3,22,6782,89,0742,81,5422,80,2482,88,5372,79,2802,81,9882,83,2102,86,6042,80,2562,88,9312,90,411

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls